[Effectiveness and safety of atezolizumab plus bevacizumab versus lenvatinib in patients with unresectable HBV-related hepatocellular carcinoma].

PubMed 2026

View at publisher
Authors: Xu Lang, B Y Liu, J Zeng
DOI: 10.3760/cma.j.cn112137-20250803-01952
Cited by: 0

Abstract

In patients with unresectable HBV-related HCC, atezolizumab plus bevacizumab demonstrated a longer OS and higher ORR compared to lenvatinib with a manageable safety profile.

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Hepatitis B Virus Studies Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
PubMed
Volume
106
Issue
6
Pages
559–565
Publication date
10 February 2026
Language
ZH